Peter Smith

Peter Smith

Company: Astra Zeneca

Job title: Director - New Modalities Chemistry


Looking at Oligonucleotide DS CMC Capabilities 2:15 pm

Early-phase oligonucleotide CMC challenges: achieving phase-appropriate controls, quality & regulatory oversight whilst maintaining agility against project delivery requirements Evolution of AstraZeneca's approach to oligonucleotide portfolio expansion drives new ways of working The expansion and uplift of internal capabilities enables the future growth of oligonucleotide DS CMC development within AstraZenecaRead more

day: Day Two

Panel Discussion: Outlining Current Industry Trends in Oligonucleotide Development 9:00 am

• Discussing the movement away from the development of oligonucleotides for rare diseases • Capitalizing on opportunities and changes we anticipate in the future and newer complex oligos coming into pipelines • Outlining challenges of COGs, scale, impurity characterization and qualificationRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.